You searched for stem cell person of the year - Page 40 of 46

New Herbert lab Nature paper reinforces mitochondrial replacement Achilles heel

June 8, 2016 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Today a new Nature paper from Dr. Mary Herbert’s group in the UK has found a key problem with mitochondrial replacement therapy that fits with data from others. Mitochondrial replacement data The goal of preventing mitochondrial disease using various kinds of genome transfer technologies is a noble one, but mitochondrial replacement therapy has faced a […]

New Herbert lab Nature paper reinforces mitochondrial replacement Achilles heel Read More »

TGIF Science: funding, CRISPR v. NgAgo, secrets, Zika, & more

May 20, 2016 / Professor Paul Knoepfler, Ph.D. / 2 Comments

Some stuff on my mind for our TGIF Science this week. Research Funding Ups: NIH. Is it my imagination or is NIH funding slightly improving? This is the overall vibe I’m hearing from the trenches. Research Funding Ups and Downs: CIRM. CIRM funded some basic research to the tune of a total of $4 million,

TGIF Science: funding, CRISPR v. NgAgo, secrets, Zika, & more Read More »

UK should freeze mitochondrial replacement as Egli paper ID’s serious problem

May 19, 2016 / Professor Paul Knoepfler, Ph.D. / 1 Comment

An important new Cell Stem Cell paper from Dieter Egli’s lab points to an inherent, serious problem with so-called 3-person IVF or mitochondrial replacement technology that warrants putting an immediate hold on all efforts to use it in humans. I have pasted the graphical abstract from the paper below. For years a few of us scientists and

UK should freeze mitochondrial replacement as Egli paper ID’s serious problem Read More »

In Depth Report from April 29th Paris Human Gene Editing Meeting

May 11, 2016 / Professor Paul Knoepfler, Ph.D.

Editor’s note. Caroline Simons attended both the April 28th (see her report on that here) and 29th Paris meetings on human gene editing/genetic modification. Today, we have her in depth report on the April 29th meeting. I have posted her piece in full with only minor edits. If you are in a rush you can

In Depth Report from April 29th Paris Human Gene Editing Meeting Read More »

Paris human gene editing workshop summary

April 29, 2016 / Professor Paul Knoepfler, Ph.D.

Editors note: This is a guest post from Caroline Simons who is attending the two Paris meetings on human gene editing. For more background on those meetings see here. By Caroline Simons There were just over a hundred participants at the workshop organized by the Federation of European Academies of Medicine, the UK Academy of

Paris human gene editing workshop summary Read More »

George Church chat: CRISPR people, Zika, weapons

April 18, 2016 / Professor Paul Knoepfler, Ph.D. / 4 Comments

I talked last year about human genetic modification by CRISPR with George Church a year ago. Now we’ve followed up with a long chat on this topic going into much more detail and with questions on recent developments. Each question is listed numerically and then there is a back and forth on that question with George

George Church chat: CRISPR people, Zika, weapons Read More »

Reviews of my new book GMO Sapiens on #CRISPR & human modification

February 16, 2016 / Professor Paul Knoepfler, Ph.D.

It’s exciting that the reviews are starting to come in on my new book, GMO Sapiens, on human genetic modification including CRISPR. Here is one from The Scientist and the book was recommended by Scientific American. Reviews from individual authors and scientists are below. “GMO Sapiens could not be more timely. New technologies like CRISPR-Cas9 gene

Reviews of my new book GMO Sapiens on #CRISPR & human modification Read More »

Ocata bought by Astellas of Japan: initial perspectives on end of an era

November 9, 2015 / Professor Paul Knoepfler, Ph.D. / 7 Comments

Bombshell news in the stem cell field as Ocata Therapeutics (OCAT; formerly Advanced Cell Technology or ACT) is reportedly to be acquired by Astellas Pharma, Inc. The offer for purchase of OCAT will be $8.50/share or almost $380 million. For more details see this detailed PDF from Astellas. This quote on the deal form Ocata: “Paul

Ocata bought by Astellas of Japan: initial perspectives on end of an era Read More »

Knoepfler Lab 2015: Our mission and research

September 15, 2015 / Professor Paul Knoepfler, Ph.D.

10403400_587299148036372_4882230830289951262_n

Many of this blog’s readers ask about my own lab’s research: what is the focus of the work in the Knoepfler Lab? You can go check out our lab website, but I thought it might be time again to blog about what we are all about as a lab and what we have been up

Knoepfler Lab 2015: Our mission and research Read More »

Did NHK Violate Rights of Obokata (小保方晴子) on STAP?

August 25, 2015 / Professor Paul Knoepfler, Ph.D. / 13 Comments

The Japanese public broadcasting system, NHK, has been accused by scientist Haruko Obokata of violating her human rights. Obokata was the primary researcher involved in the STAP cell fiasco in which two ultimately retracted Nature papers contained duplicated, plagiarized, and manipulated data. She was certainly not the only researcher on those papers, but overall she

Did NHK Violate Rights of Obokata (小保方晴子) on STAP? Read More »

Search Results for: stem cell person of the year